Effect of the anti-neoplastic drug doxorubicin on XPD-mutated DNA repair-deficient human cells
- 2 January 2010
- journal article
- research article
- Published by Elsevier BV in DNA Repair
- Vol. 9 (1), 40-47
- https://doi.org/10.1016/j.dnarep.2009.10.003
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Detection of Adriamycin–DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrationsNucleic Acids Research, 2008
- DNA repair in response to anthracycline–DNA adducts: A role for both homologous recombination and nucleotide excision repairMutation research. Reviews in mutation research, 2008
- Oxidative DNA base damage in MCF-10A breast epithelial cells at clinically achievable concentrations of doxorubicinBiochemical Pharmacology, 2007
- Adriamycin-induced myocardial toxicity: New solutions for an old problem?International Journal of Cardiology, 2007
- The Power and Potential of Doxorubicin‐DNA AdductsIUBMB Life, 2005
- Basal, oxidative and alkylative DNA damage, DNA repair efficacy and mutagen sensitivity in breast cancerMutation research. Reviews in mutation research, 2004
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPharmacological Reviews, 2004
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999
- Long-term complementation of DNA repair deficient human primary fibroblasts by retroviral transduction of the XPD geneMutation Research/DNA Repair, 1996
- The kinetics of repair of oxidative DNA damage (strand breaks and oxidised pyrimidines) in human cellsMutation Research/DNA Repair, 1995